Insmed Incorporated · 2 days ago
Vice President, Product Development – CMC, Gene Therapy and Large Molecules
Headquarters, NJ
Full-time
Hybrid
Director/Executive
$329K/yr - $398K/yr
12+ years expInsmed Incorporated is a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases. They are seeking a highly experienced Vice President of Product Development to lead their gene therapy and large molecules pipeline from preclinical through clinical development and regulatory approvals, while building high-performing teams and fostering a culture of innovation.
BiotechnologyMedicalPharmaceutical
Responsibilities
Define and execute the product development strategy for all gene therapy and large molecule programs, providing strategic direction and oversight throughout the development lifecycle and up through product approvals and launch
Oversee clinical development activities by working collaboratively with cross-functional leaders to ensure seamless execution of clinical trials and achieve regulatory milestones
Coordinate efforts across multiple departments to advance gene therapy and large molecule pipelines
Ensure that all Chemistry, Manufacturing, and Controls activities result in manufacturable, scalable, and compliant processes while maintaining supply chain readiness for both clinical and commercial needs
Support global regulatory strategies by contributing to IND filings, BLA submissions, and pursuing orphan and rare disease designations that align with therapeutic focus areas
Build and mentor a high-performing product development team where you will foster a culture of innovation and accountability while developing talent within the organization
Collaborate with external stakeholders including Contract Development and Manufacturing Organizations (CDMOs) and raw material suppliers to ensure reliable partnerships that support development timelines and quality standards
Qualification
Required
PhD, or advanced degree in molecular biology, biotechnology, chemical engineering, or related field
12–15+ years of progressive leadership experience in biopharma, with a strong track record in gene therapy or advanced biologics
Demonstrated success in advancing therapies through IND, clinical development and regulatory approvals
Deep understanding of vector biology (AAV, etc.), CMC requirements, and manufacturing for gene therapy
Strong leadership, communication, and organizational skills with proven ability to influence at all levels
Strategic thinker with the ability to operate effectively in a dynamic, fast-paced environment
Benefits
Comprehensive medical, dental, and vision coverage and mental health support, annual wellbeing reimbursement, and access to our Employee Assistance Program (EAP)
Generous paid time off policies, fertility and family-forming benefits, caregiver support, and flexible work schedules with purposeful in-person collaboration
401(k) plan with a competitive company match, annual equity awards, and participation in our Employee Stock Purchase Plan (ESPP), and company-paid life and disability insurance
Company Learning Institute providing access to LinkedIn Learning, skill building workshops, leadership programs, mentorship connections, and networking opportunities
Employee resource groups, service and recognition programs, and meaningful opportunities to connect, volunteer, and give back
Company
Insmed Incorporated
Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases.
1001-5000 employees
H1B Sponsorship
Insmed Incorporated has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (20)
2024 (6)
2023 (14)
2022 (8)
2021 (1)
2020 (5)
Funding
Current Stage
Public CompanyTotal Funding
$4.56BKey Investors
CureDuchenne Ventures
2025-06-11Post Ipo Equity· $750M
2024-05-30Post Ipo Equity· $650M
2023-05-08Post Ipo Equity· $0.5M
Leadership Team
Will Lewis
Chairman and Chief Executive officer
Walter R. Perkins
Chief Technology Officer
Recent News
2026-01-13
2026-01-11
Company data provided by crunchbase